Teva Pharmaceutical Industries (TEVA) Other Accumulated Expenses (2009 - 2026)

Teva Pharmaceutical Industries (TEVA) has 18 years of Other Accumulated Expenses data on file, last reported at $987.0 million in Q2 2026.

• Quarterly Other Accumulated Expenses rose 5.0% year-over-year to $987.0 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $987.0 million (up 5.0% YoY) and the FY2025 annual result came in at $1.2 billion, up 15.88% from the prior year.
• Other Accumulated Expenses eased to $987.0 million in Q2 2026, from $1.1 billion in the prior quarter.
• In the past five years, Other Accumulated Expenses ranged from a high of $1.2 billion in Q3 2024 to a low of $900.0 million in Q1 2022.
• A 5-year average of $1.0 billion and a median of $1.0 billion in 2022 frame the typical range for Other Accumulated Expenses.
• Annual changes were most pronounced in 2024 — Other Accumulated Expenses climbed 22.75% — and 2025, when it dropped 21.07%.
• Tracing TEVA's Other Accumulated Expenses over 5 years: stood at $1.0 billion in 2022, then advanced by 3.88% to $1.0 billion in 2023, then decreased by 2.3% to $1.0 billion in 2024, then increased by 15.88% to $1.2 billion in 2025, then decreased by 16.5% to $987.0 million in 2026.
• The last three Other Accumulated Expenses figures came in at $987.0 million (Q2 2026), $1.1 billion (Q1 2026), and $1.2 billion (Q4 2025), per Business Quant data.